Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery

Proteomics - Clinical Applications

Volumn 7, Issue 1-2, 2013, Pages 123-135

  Krüger, Thomas ^a   Lautenschläger, Janin ^a   Grosskreutz, Julian ^a   Rhode, Heidrun ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Amyotrophic lateral sclerosis; Biomarker; Body fluids; Motor neuron disease; Riluzole

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANGIOGENIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYSTATIN C; CYTOCHROME C; ERYTHROPOIETIN; FERRITIN; FIBRONECTIN; GALECTIN 3; GELATINASE B; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; INTERLEUKIN 8; NEUROEN DOCRINE PROTEIN 7B2; NEUROFILAMENT HEAVY POLYPEPTIDE; NEUROFILAMENT LIGHT POLYPEPTIDE; PREALBUMIN; PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TAR DNA BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE MARKER; GENE; GENETIC HETEROGENEITY; HUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SALIVA ANALYSIS; SOD1 GENE; URINALYSIS; VALIDATION PROCESS;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; BODY FLUIDS; HUMANS; PROTEOME; PROTEOMICS;

EID: 84872731142     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200067     Document Type: Review

References (109)

1. Goetz, C. G., Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle Nerve 2000, 23, 336-343.
2. Chio, A., Logroscino, G., Traynor, B., Collins, J. et al., Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. J. Neurol. 2012, 259, S51-S52.
3. Plato, C. C., Garruto, R. M., Galasko, D., Craig, U. K. et al., Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am. J. Epidemiol. 2003, 157, 149-157.
4. Araki, S., Iwahashi, Y., Kuroiwa, Y., Epidemiological study of amyotrophic lateral sclerosis and allied disorders in Kii Peninsula (Japan). J. Neurol. Sci. 1967, 4, 279-287.
5. Chio, A., Calvo, A., Moglia, C., Mazzini, L. et al., Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J. Neurol. Neurosur. Psychiatry 2011, 82, 740-746.
6. Brooks, B. R., Miller, R. G., Swash, M., Munsat, T. L. et al., El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler. 2000, 1, 293-299.
7. de Carvalho, M., Dengler, R., Eisen, A., England, J. D. et al., Electrodiagnostic criteria for diagnosis of ALS. Clin. Neurophysiol. 2008, 119, 497-503.
8. Ekegren, T., Hanrieder, J., Bergquist, J., Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience-exemplified in amyotrophic lateral sclerosis biomarker discovery research. J. Mass Spectrom. 2008, 43, 559-571.
9. Li, T. M., Alberman, E., Swash, M., Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease. J. Neurol. Neurosurg. Psychiatry 1988, 51, 778-784.
10. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A. et al., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59-62.
11. Nishimura, A. L., Mitne-Neto, M., Silva, H. C. A., Richieri-Costa, A. et al., A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 2004, 75, 822-831.
12. Greenway, M. J., Andersen, P. M., Russ, C., Ennis, S. et al., ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet. 2006, 38, 411-413.
13. Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X. et al., TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319, 1668-1672.
14. Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D. et al., TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40, 572-574.
15. Kwiatkowski, T. J., Jr., Bosco, D. A., LeClerc, A. L., Tamrazian, E. et al., Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323, 1205-1208.
16. Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J. et al., Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323, 1208-1211.
17. Maruyama, H., Morino, H., Ito, H., Izumi, Y. et al., Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465, 223-U109.
18. Johnson, J. O., Mandrioli, J., Benatar, M., Abramzon, Y. et al., Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010, 68, 857-864.
19. Koppers, M., van Blitterswijk, M. M., Vlam, L., Rowicka, P. A. et al., VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33, e7-13.
20. Deng, H.-X., Chen, W., Hong, S.-T., Boycott, K. M. et al., Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477, U211-U113.
21. DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L. et al., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72, 245-256.
22. Renton, A. E., Majounie, E., Waite, A., Simon-Sanchez, J. et al., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72, 257-268.
23. Wu, C. H., Fallini, C., Ticozzi, N., Keagle, P. J. et al., Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012, 488, 499-503.
24. Jones, C. T., Brock, D. J. H., Chancellor, A. M., Warlow, C. P. et al., Cu/Zn superoxide dismutase (SOD1) mutations and sporadic amyotrophic lateral sclerosis. Lancet 1993, 342, 1050-1051.
25. Sabatelli, M., Conforti, F. L., Zollino, M., Mora, G. et al., C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiol. Aging 2012, 33, 1848.e1815-1848.e1820.
26. Lowe, J., New pathological findings in amyotrophic lateral sclerosis. J. Neurol. Sci. 1994, 124, 38-51.
27. Shibata, N., Hirano, A., Kobayashi, M., Sasaki, S. et al., Cu/Zn superoxide dismutase-like Immunoreactivity in Lewy body-like inclusions of sporadic amyotrophic lateral sclerosis. Neurosci. Lett. 1994, 179, 149-152.
28. Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C. et al., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314, 130-133.
29. Deng, H.-X., Zhai, H., Bigio, E. H., Yan, J. et al., FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann. Neurol. 2010, 67, 739-748.
30. Basso, M., Samengo, G., Nardo, G., Massignan, T. et al., Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS ONE 2009, 4, e8130.
31. Jung, C. W., Higgins, C. M. J., Xu, Z. S., Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J. Neurochem. 2002, 83, 535-545.
32. Damiano, M., Starkov, A. A., Petri, S., Kipiani, K. et al., Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J. Neurochem. 2006, 96, 1349-1361.
33. Murata, T., Ohtsuka, C., Terayama, Y., Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J. Neurol.l Sci. 2008, 267, 66-69.
34. Guegn, C., Vila, M., Rosoklija, G., Hays, A. P., Przedborski, S., Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Neurosci. 2001, 21, 6569-6576.
35. Li, P. F., Dietz, R., von Harsdorf, R., p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J. 1999, 18, 6027-6036.
36. Lobner, D., Piana, P. M. T., Salous, A. K., Peoples, R. W., beta-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol.Dis. 2007, 25, 360-366.
37. Chiu, A. S., Gehringer, M. M., Braidy, N., Guillemin, G. J. et al., Excitotoxic potential of the cyanotoxin beta-methyl-amino-l-alanine (BMAA) in primary human neurons. Toxicon 2012, 60, 1159-1165.
38. Siklos, L., Engelhardt, J., Harati, Y., Smith, R. G. et al., Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann. Neurol. 1996, 39, 203-216.
39. Lautenschlaeger, J., Prell, T., Grosskreutz, J., Endoplasmic reticulum stress and the ER mitochondrial calcium cycle in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012, 13, 166-177.
40. Pasinelli, P., Brown, R. H., Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 2006, 7, 710-723.
41. Munoz, D. G., Greene, C., Perl, D. P., Selkoe, D. J., Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J. Neuropathol. Exp. Neurol. 1988, 47, 9-18.
42. Morotz, G. M., De Vos, K. J., Vagnoni, A., Ackerley, S. et al., Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria. Hum. Mol. Genet. 2012, 21, 1979-1988.
43. Fan, J., Hu, Z., Zeng, L., Lu, W. et al., Golgi apparatus and neurodegenerative diseases. Int. J. Dev.l Neurosci. 2008, 26, 523-534.
44. Kushner, P. D., Stephenson, D. T., Wright, S., Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. J. Neuropathol. Exp. Neurol. 1991, 50, 263-277.
45. Kawamata, T., Akiyama, H., Yamada, T., McGeer, P. L., Immunological reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992, 140, 691-707.
46. Hall, E. D., Oostveen, J. A., Gurney, M. E., Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23, 249-256.
47. Turner, M. R., Kiernan, M. C., Leigh, P. N., Talbot, K., Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009, 8, 94-109.
48. Biomarkers Definitions Working, G., Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89-95.
49. Otto, M., Bowser, R., Turner, M., Berry, J. et al., Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph. Lateral Scler. 2012, 13, 1-10.
50. Diz, A. P., Truebano, M., Skibinski, D. O. F., The consequences of sample pooling in proteomics: an empirical study. Electrophoresis 2009, 30, 2967-2975.
51. Noto, Y. I., Shibuya, K., Sato, Y., Kanai, K. et al., Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph. Lateral Scler. 2011, 12, 140-143.
52. Shi, M., Caudle, W. M., Zhang, J., Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol. Dis. 2009, 35, 157-164.
53. Dekker, L. J., Burgers, P. C., Kros, J. M., Smitt, P. A. E. S., Luider, T. M., Peptide profiling of cerebrospinal fluid by mass spectrometry. Expert Rev. Proteomics 2006, 3, 297-309.
54. Zhang, J., Goodlett, D. R., Montine, T. J., Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. J. Alzheimers Dis. 2005, 8, 377-386.
55. Polaskova, V., Kapur, A., Khan, A., Molloy, M. P. et al., High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis 2010, 31, 471-482.
56. Bowser, R., Turner, M. R., Shefner, J., Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat. Rev. Neurol. 2011, 7, 631-638.
57. Pasinetti, G. M., Ungar, L. H., Lange, D. J., Yemul, S. et al., Identification of potential CSF biomarkers in ALS. Neurology 2006, 66, 1218-1222.
58. Ranganathan, S., Williams, E., Ganchev, P., Gopalakrishnan, V. et al., Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J.f Neurochem. 2005, 95, 1461-1471.
59. Brettschneider, J., Lehmensiek, V., Mogel, H., Pfeifle, M. et al., Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci. Lett. 2010, 468, 23-27.
60. Brettschneider, J., Mogel, H., Lehmensiek, V., Ahlert, T. et al., Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem. Res. 2008, 33, 2358-2363.
61. Sjogren, M., Davidson, P., Wallin, A., Granerus, A. K. et al., Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Dis. 2002, 13, 112-118.
62. Ilzecka, J., Stelmasiak, Z., Dobosz, B., Interleukin-1beta converting enzyme/Caspase-1 (ICE/Caspase-1) and soluble APO-1/Fas/CD 95 receptor in amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 2001, 103, 255-258.
63. Tanaka, M., Kikuchi, H., Ishizu, T., Minohara, M. et al., Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2006, 65, 816-825.
64. Kuhle, J., Lindberg, R. L. P., Regeniter, A., Mehling, M. et al., Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 2009, 16, 771-774.
65. Ganesalingam, J., An, J., Shaw, C. E., Shaw, G. et al., Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J. Neurochem. 2011, 117, 528-537.
66. Tsuboi, Y., Yamada, T., Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J.f Neurol.Neurosurg. Psychiatry 1994, 57, 859-861.
67. Ilzecka, J., Decreased cerebrospinal fluid cytochrome c levels in patients with amyotrophic lateral sclerosis. Scand. J. Clin. Lab. Invest. 2007, 67, 264-269.
68. Brettschneider, J., Widl, K., Schattauer, D., Ludolph, A. C. et al., Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neurosci. Lett. 2007, 416, 257-260.
69. Zhou, J.-Y., Afjehi-Sadat, L., Asress, S., Duong, D. M. et al., Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. J. Proteome Res. 2010, 9, 5133-5141.
70. Grundström, E., Lindholm, D., Johansson, A., Blennow, K. et al., GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport 2000, 11, 1781-1783.
71. Bilic, E., Rudan, I., Kusec, V., Zurak, N. et al., Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur. J. Neurol. 2006, 13, 1340-1345.
72. Sekizawa, T., Openshaw, H., Ohbo, K., Sugamura, K. et al., Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J. Neurol. Sci. 1998, 154, 194-199.
73. Mitchell, R. M., Freeman, W. M., Randazzo, W. T., Stephens, H. E. et al., A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009, 72, 14-19.
74. Brettschneider, J., Petzold, A., Sussmuth, S. D., Ludolph, A. C., Tumani, H., Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006, 66, 852-856.
75. Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K. et al., Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur. J. Neurol. 2007, 14, 1329-1333.
76. Rosengren, L. E., Karlsson, J. E., Karlsson, J. O., Persson, L. I. et al., Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 1996, 67, 2013-2018.
77. Matsuishi, T., Nagamitsu, S., Shoji, H., Itoh, M. et al., Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis. J. Neural Transm. 1999, 106, 943-948.
78. Kasai, T., Tokuda, T., Ishigami, N., Sasayama, H. et al., Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009, 117, 55-62.
79. Fujita, K., Honda, M., Hayashi, R., Ogawa, K. et al., Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: a possible use as an indicator of extent of the motor neuron loss. J. Neurol. Sci. 1998, 158, 53-57.
80. Moreau, C., Devos, D., Brunaud-Danel, V., Defebvre, L. et al., Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J. Neurol. Neurosurg. Psychiatry 2006, 77, 255-257.
81. Cronin, S., Greenway, M. J., Ennis, S., Kieran, D. et al., Elevated serum angiogenin levels in ALS. Neurology 2006, 67, 1833-1836.
82. Simpson, E. P., Henry, Y. K., Henkel, J. S., Smith, R. G. et al., Increased lipid peroxidation in sera of ALS patients-a potential biomarker of disease burden. Neurology 2004, 62, 1758-1765.
83. Qureshi, M., Brown, R. H., Jr., Rogers, J. T., Cudkowicz, M. E., Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol. J. 2008, 2, 51-54.
84. Goodall, E. F., Haque, M. S., Morrison, K. E., Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. J. Neurol. 2008, 255, 1652-1656.
85. Hosback, S., Hardiman, O., Nolan, C. M., Doyle, M. A. C. et al., Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm. IGF Res. 2007, 17, 472-479.
86. Ono, S., Hu, S. G., Shimizu, N., Imai, T. et al., Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J. Neurol. Sci. 2001, 187, 27-34.
87. Beuche, W., Yushchenko, M., Mader, M., Maliszewska, M. et al., Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 2000, 11, 3419-3422.
88. Poloni, M., Facchetti, D., Mai, R., Micheli, A. et al., Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 2000, 287, 211-214.
89. Ono, S., Imai, T., Shimizu, N., Nakayama, M. et al., Decreased plasma levels of fibronectin in amyotrophic lateral sclerosis. Acta Neurol. Scand. 2000, 101, 391-394.
90. Verstraete, E., Kuiperij, H. B., van Blitterswijk, M. M., Veldink, J. H. et al., TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012, 13, 446-451.
91. Houi, K., Kobayashi, T., Kato, S., Mochio, S. et al., Increased plasma TGF-beta 1 in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2002, 106, 299-301.
92. Ono, S., Imai, T., Matsubara, S., Takahashi, K. et al., Decreased urinary concentrations of type IV collagen in amyotrophic lateral sclerosis. Acta Neurol. Scand. 1999, 100, 111-116.
93. Obayashi, K., Sato, K., Shimazaki, R., Ishikawa, T. et al., Salivary chromogranin A: useful and quantitative biochemical marker of affective state in patients with amyotrophic lateral sclerosis. Int. Med. 2008, 47, 1875-1879.
94. Suessmuth, S. D., Brettschneider, J., Ludolph, A. C., Tumani, H., Biochemical markers in CSF of ALS patients. Curr. Med. Chem. 2008, 15, 1788-1801.
95. Tumani, H., Teunissen, C., Süssmuth, S., Otto, M. et al., Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev. of Mol. Diagn. 2008, 8, 479-494.
96. Kuhle, J., Leppert, D., Petzold, A., Regeniter, A. et al., Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011, 76, 1206-1213.
97. Süssmuth, S. D., Tumani, H., Ecker, D., Ludolph, A. C., Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci. Lett. 2003, 353, 57-60.
98. Paladino, P., Valentino, F., Piccoli, T., Piccoli, F. et al., Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur. J. Neurol. 2009, 16, 257-261.
99. Conti, A., Iannaccone, S., Sferrazza, B., De Monte, L. et al., Differential expression of ceruloplasmin isoforms in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Proteomics Clin. Appl. 2008, 2, 1628-1637.
100. Dengler, R., von Neuhoff, N., Bufler, J., Krampfl, K. et al., Amyotrophic lateral sclerosis: new developments in diagnostic markers. Neurodegener. dis. 2005, 2, 177-184.
101. Ono, S., Shimizu, N., Imai, T., Rodriguez, G. P., Urinary collagen metabolite excretion in amyotrophic lateral sclerosis. Muscle Nerve 2001, 24, 821-825.
102. Ono, S., Imai, T., Munakata, S., Takahashi, K. et al., Collagen abnormalities in the spinal cord from patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences 1998, 160, 140-147.
103. Ono, S., Mechanic, G. L., Yamauchi, M., Amyotrophic lateral sclerosis: unusually low content of collagen in skin. J. Neurol. Sci. 1990, 100, 234-237.
104. Suessmuth, S. D., Sperfeld, A. D., Hinz, A., Brettschneider, J. et al., CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 2010, 74, 982-987.
105. Lacomblez, L., Doppler, V., Beucler, I., Costes, G. et al., APOE: a potential marker of disease progression in ALS. Neurology 2002, 58, 1112-1114.
106. Ganesalingam, J., Bowser, R., The application of biomarkers in clinical trials for motor neuron disease. Biomark. Med. 2010, 4, 281-297.
107. Bowser, R., Lacomis, D., Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve 2009, 40, 753-762.
108. Miller, R. G., Mitchell, J. D., Moore, D. H., Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2012, DOI: 10.1002/14651858.CD001447.pub3.
109. Bellingham, M. C., A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci. Ther. 2011, 17, 4-31.